Overview

Efficacy and Safety of GTR in Comparison to Copaxone®

Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is demonstrate that efficacy and safety of Synthon's glatiramer acetate (GTR) is equivalent to Copaxone® (Teva) in patients with relapsing remitting multiple sclerosis
Phase:
Phase 3
Details
Lead Sponsor:
Synthon BV
Treatments:
(T,G)-A-L
Glatiramer Acetate